Ivabradine | CAS# 155974-00-8 | bradycardic agent

MedKoo Cat#: 413280 | Name: Ivabradine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ivabradine is a bradycardic agent; S-16257-2 is the (S)-isomer; S-16260-2 is the (R)-isomer; both (S)- and (R)-isomers have activity.

Chemical Structure

Ivabradine

CAS#155974-00-8 (free base)

Theoretical Analysis

MedKoo Cat#: 413280

Name: Ivabradine

CAS#: 155974-00-8 (free base)

Chemical Formula: C27H36N2O5

Exact Mass: 468.2624

Molecular Weight: 468.59

Elemental Analysis: C, 69.21; H, 7.74; N, 5.98; O, 17.07

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

155974-00-8 (free base) 1202000-62-1 (sulfate) 148849-67-6 (HCl) 1086026-42-7 (oxalate) 1422274-66-5 (hemisulfate)

Synonym

Ivabradine; S16257; S-16257; S 16257; S16257-2; S-16257-2; S 16257-2

IUPAC/Chemical Name

2H-3-Benzazepin-2-one, 3-(3-(((3,4-dimethoxybicyclo(4.2.0)octa-1,3,5-trien-7-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-, (S)-

InChi Key

ACRHBAYQBXXRTO-OAQYLSRUSA-N

InChi Code

InChI=1S/C27H36N2O5/c1-28(17-21-11-20-14-25(33-4)26(34-5)16-22(20)21)8-6-9-29-10-7-18-12-23(31-2)24(32-3)13-19(18)15-27(29)30/h12-14,16,21H,6-11,15,17H2,1-5H3/t21-/m1/s1

SMILES Code

O=C1N(CCCN(C[C@@H]2C3=CC(OC)=C(OC)C=C3C2)C)CCC4=CC(OC)=C(OC)C=C4C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

	Solvent	mg/mL	mM
Solubility
	Soluble in DMSO	0.0	100.00

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 468.59 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Ide T, Ohtani K, Higo T, Tanaka M, Kawasaki Y, Tsutsui H. Ivabradine for the Treatment of Cardiovascular Diseases. Circ J. 2019 Jan 25;83(2):252-260. doi: 10.1253/circj.CJ-18-1184. Epub 2018 Dec 29. PMID: 30606942. 2: Bocchi EA, Salemi VMC. Ivabradine for treatment of heart failure. Expert Opin Drug Saf. 2019 May;18(5):393-402. doi: 10.1080/14740338.2019.1612873. Epub 2019 May 10. PMID: 31074301. 3: Komajda M. Ivabradine. Handb Exp Pharmacol. 2017;243:167-175. doi: 10.1007/164_2016_55. PMID: 27752846. 4: Koruth JS, Lala A, Pinney S, Reddy VY, Dukkipati SR. The Clinical Use of Ivabradine. J Am Coll Cardiol. 2017 Oct 3;70(14):1777-1784. doi: 10.1016/j.jacc.2017.08.038. PMID: 28958335. 5: Chiu MH, Howlett JG, Sharma NC. Initiation of ivabradine in cardiogenic shock. ESC Heart Fail. 2019 Oct;6(5):1088-1091. doi: 10.1002/ehf2.12499. Epub 2019 Jul 23. PMID: 31332966; PMCID: PMC6816060. 6: Dallapellegrina L, Sciatti E, Vizzardi E. Ivabradine and endothelium: an update. Ther Adv Cardiovasc Dis. 2020 Jan-Dec;14:1753944720934937. doi: 10.1177/1753944720934937. PMID: 32611276; PMCID: PMC7333483. 7: Tsutsui H, Momomura SI, Yamashina A, Shimokawa H, Kihara Y, Saito Y, Hagiwara N, Ito H, Yano M, Yamamoto K, Ako J, Inomata T, Sakata Y, Tanaka T, Kawasaki Y; J-SHIFT Study Investigators. Efficacy and Safety of Ivabradine in Japanese Patients With Chronic Heart Failure　- J-SHIFT Study. Circ J. 2019 Sep 25;83(10):2049-2060. doi: 10.1253/circj.CJ-19-0227. Epub 2019 Aug 8. PMID: 31391387. 8: Zhou Y, Wang J, Meng Z, Zhou S, Peng J, Chen S, Wang Q, Sun K. Pharmacology of Ivabradine and the Effect on Chronic Heart Failure. Curr Top Med Chem. 2019;19(21):1878-1901. doi: 10.2174/1568026619666190809093144. PMID: 31400267. 9: Pei H, Miao W, Xie WZ, Wang W, Zhao D, Su GH, Zhao Z. Ivabradine Improves Cardiac Function and Increases Exercise Capacity in Patients with Chronic Heart Failure. Int Heart J. 2019 Jul 27;60(4):899-909. doi: 10.1536/ihj.18-559. Epub 2019 Jul 12. PMID: 31308326. 10: Simko F, Baka T, Poglitsch M, Repova K, Aziriova S, Krajcirovicova K, Zorad S, Adamcova M, Paulis L. Effect of Ivabradine on a Hypertensive Heart and the Renin-Angiotensin-Aldosterone System in L-NAME-Induced Hypertension. Int J Mol Sci. 2018 Oct 3;19(10):3017. doi: 10.3390/ijms19103017. PMID: 30282928; PMCID: PMC6212851.